Your browser is no longer supported. Please, upgrade your browser.
Settings
NK NantKwest, Inc. daily Stock Chart
NK [NASD]
NantKwest, Inc.
Index- P/E- EPS (ttm)-1.27 Insider Own1.50% Shs Outstand76.94M Perf Week-7.52%
Market Cap416.25M Forward P/E- EPS next Y-1.47 Insider Trans-16.22% Shs Float27.56M Perf Month0.00%
Income-104.10M PEG- EPS next Q-0.32 Inst Own19.00% Short Float15.40% Perf Quarter-22.38%
Sales0.05M P/S8161.67 EPS this Y55.50% Inst Trans-7.95% Short Ratio11.85 Perf Half Y57.73%
Book/sh3.11 P/B1.74 EPS next Y-17.60% ROA-33.20% Target Price4.67 Perf Year-30.64%
Cash/sh2.28 P/C2.37 EPS next 5Y-1.70% ROE-36.70% 52W Range2.71 - 8.45 Perf YTD-5.42%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-34.91% Beta-
Dividend %- Quick Ratio4.90 Sales past 5Y- Gross Margin- 52W Low102.95% ATR0.34
Employees104 Current Ratio4.90 Sales Q/Q16.70% Oper. Margin- RSI (14)38.75 Volatility6.05% 6.33%
OptionableYes Debt/Eq0.07 EPS Q/Q30.60% Profit Margin- Rel Volume0.62 Prev Close5.41
ShortableYes LT Debt/Eq0.01 EarningsAug 21 Payout- Avg Volume358.33K Price5.50
Recom3.00 SMA20-6.49% SMA50-9.64% SMA2005.25% Volume221,901 Change1.66%
May-16-17Downgrade Citigroup Neutral → Sell
Mar-17-17Reiterated FBR & Co. Outperform $22 → $9
Jan-24-17Downgrade Jefferies Buy → Hold
Jun-02-16Initiated Raymond James Mkt Perform
Apr-04-16Reiterated Canaccord Genuity Buy $20 → $18
Mar-31-16Reiterated FBR Capital Outperform $30 → $29
Dec-22-15Initiated Canaccord Genuity Buy $20
Oct-28-15Initiated FBR Capital Outperform $30
Aug-24-15Initiated Piper Jaffray Overweight $38
Aug-24-15Initiated MLV & Co Buy $35
Aug-24-15Initiated Jefferies Buy $33
Aug-24-15Initiated Citigroup Buy $45
Sep-21-17 08:01AM  NANTKWEST (NK) SHAREHOLDER ALERT Andrews & Springer LLC is Investigating NantKwest, Inc. for Potential Breaches of Fiduciary Duty Business Wire
Aug-31-17 07:38PM  ETFs with exposure to NantKwest, Inc. : August 31, 2017 Capital Cube +9.88%
Aug-24-17 10:11AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube +6.14%
Aug-15-17 06:18PM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : August 15, 2017 Capital Cube
Aug-09-17 11:50AM  Here's Why NantKwest Inc. Tumbled 21.1% in July Motley Fool
Aug-07-17 12:59PM  NantKwest to Present at the 37th Annual Canaccord Genuity Growth Conference Business Wire
Aug-02-17 09:12AM  NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : August 2, 2017 Capital Cube
Jul-31-17 11:00AM  NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies Business Wire
Jul-27-17 09:00AM  Haeggquist & Eck Investigates NantKwest for Misrepresenting Compensation to CEO by $49 Million and Breach of Fiduciary Duty Business Wire -7.83%
Jul-25-17 08:00AM  NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials Business Wire
Jul-18-17 08:10AM  5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote Zacks
Jul-14-17 09:00AM  Haeggquist & Eck, LLP Investigates NantKwest Inc. for Potential Breaches of Fiduciary Duty by Its Board of Directors Business Wire
Jun-21-17 09:30AM  Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago Zacks -5.79%
Jun-20-17 05:37PM  How to Uncover Institutional Buying Zacks
Jun-19-17 03:48PM  ETFs with exposure to NantKwest, Inc. : June 19, 2017 Capital Cube +9.26%
Jun-16-17 08:15AM  NantKwest (NK) Looks Good: Stock Moves Up 8.5% in Session Zacks +5.37%
Jun-14-17 02:09PM  2 Longs And 2 Shorts To Watch Benzinga
Jun-06-17 08:00AM  NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease Business Wire +6.27%
Jun-02-17 06:55AM  NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017 Business Wire +6.48%
May-23-17 09:29AM  Biotech Movers: Cerus, Alexion, NantKwest TheStreet.com +6.46%
May-18-17 08:00AM  NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs Business Wire
May-16-17 05:02PM  Why Rite Aid, H&R Block, and NantKwest Slumped Today Motley Fool -17.17%
08:00AM  NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology Business Wire
May-15-17 06:24PM  NantKwest to Present at 2017 Bank of America Merrill Lynch Healthcare Conference Business Wire +15.58%
04:15PM  ETFs with exposure to NantKwest, Inc. : May 15, 2017 Capital Cube
02:34PM  Why NantKwest Stock Is Spiking Today Motley Fool
08:17AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : May 15, 2017 Capital Cube
May-10-17 10:52AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 Capital Cube
May-09-17 07:00AM  NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer Business Wire +9.19%
06:00AM  NantKwest reports 1Q loss Associated Press
May-04-17 04:11PM  ETFs with exposure to NantKwest, Inc. : May 4, 2017 Capital Cube
Apr-24-17 02:37PM  ETFs with exposure to NantKwest, Inc. : April 24, 2017 Capital Cube
Apr-07-17 05:08PM  ETFs with exposure to NantKwest, Inc. : April 7, 2017 Capital Cube
Apr-04-17 03:03PM  [$$] Funding Snapshot: Viracta Gets $18.4 Million from NantKwest for Cancer Drugs The Wall Street Journal
03:03PM  [$$] Funding Snapshot: Viracta Gets $18.4 Million from NantKwest for Cancer Drugs
08:00AM  NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership GlobeNewswire
08:00AM  NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
Mar-27-17 04:01PM  ETFs with exposure to NantKwest, Inc. : March 27, 2017 Capital Cube +6.19%
04:01PM  ETFs with exposure to NantKwest, Inc. : March 27, 2017
Mar-21-17 01:04PM  NANTKWEST, INC. Financials -6.76%
11:38AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube
11:38AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
09:59AM  NantKwest, Inc. :NK-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
Mar-20-17 07:00AM  NantKwest Announces FDA Grant of Orphan Drug Designation for the Companys aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma Business Wire
Mar-15-17 04:22PM  NANTKWEST, INC. Files SEC form 10-K, Annual Report +7.02%
Mar-06-17 05:00AM  NantKwest to Present at Upcoming Investor Conferences Business Wire -5.15%
Jan-24-17 09:26AM  Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo -11.44%
06:44AM  NantKwest downgraded by Jefferies
Jan-23-17 12:47PM  Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer Business Wire
Jan-11-17 11:18AM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : January 11, 2017 Capital Cube
11:18AM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : January 11, 2017
Jan-10-17 07:19AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : January 10, 2017 Capital Cube
07:19AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : January 10, 2017
Dec-19-16 05:00AM  NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs Business Wire
Dec-16-16 02:05PM  ETFs with exposure to NantKwest, Inc. : December 16, 2016
12:13AM  How Nantkwest Inc (NK) Stacks Up Versus Peers at Insider Monkey
Dec-12-16 11:44AM  NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium Business Wire
Dec-08-16 08:43AM  Why NantKwest (NK) Stock Might be a Great Pick
Nov-29-16 07:27AM  NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : November 29, 2016
Nov-28-16 01:13PM  NantKwest to Present at the Piper Jaffray 28th Annual Health Care Conference Business Wire -5.49%
Nov-23-16 01:17PM  ETFs with exposure to NantKwest, Inc. : November 23, 2016
Nov-22-16 08:17PM  Direct Injection of CAR-Engineered CD19.taNK Cells Demonstrating Potential Vaccine Protective Effect to be Highlighted in Oral Presentation at the 58th Annual Meeting of the American Society of Hematology Business Wire
11:43AM  NantKwest Announces Landmark Study Published on high affinity haNK Cell Therapy in the Journal Oncotarget Business Wire
Nov-21-16 10:38AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016
Nov-14-16 04:08PM  NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors Business Wire
Nov-11-16 07:02AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : November 11, 2016
Nov-10-16 04:05PM  NANTKWEST, INC. Files SEC form 10-Q, Quarterly Report
Nov-08-16 08:21PM  NantKwest to Present Data at the 58th Annual Meeting of the American Society of Hematology Business Wire
Oct-24-16 12:27PM  ETFs with exposure to NantKwest, Inc. : October 24, 2016
Oct-19-16 07:05AM  Better Buy: NantKwest, Inc. vs. Celldex Therapeutics, Inc. at Motley Fool
Oct-04-16 10:00AM  Altor BioScience Corporation and NantKwest Inc. Announce Co-Development Agreement to Advance Innovative Natural Killer Cell Combination Immunotherapies for the Treatment of Cancer Business Wire
Oct-03-16 12:24PM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : October 3, 2016
07:00AM  NantKwest Announces Presentations at the Upcoming 16th Annual Meeting of the Society for Natural Immunity Business Wire
Sep-30-16 08:25AM  NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : September 30, 2016 +5.14%
Sep-21-16 10:51AM  ETFs with exposure to NantKwest, Inc. : September 21, 2016
Sep-10-16 10:36PM  NantKwest Announces Presentations at Upcoming Investment Conferences Business Wire
05:55PM  Are These 3 Clinical-Stage Biotechs Still Buys After Soaring in August? at Motley Fool
Aug-31-16 11:39AM  ETFs with exposure to NantKwest, Inc. : August 31, 2016
Aug-29-16 06:09AM  NANTKWEST, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Aug-19-16 01:04PM  ETFs with exposure to NantKwest, Inc. : August 19, 2016
Aug-18-16 11:05AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016
Aug-16-16 06:20AM  NantKwest reports 2Q loss
Aug-15-16 12:04PM  NANTKWEST, INC. Files SEC form 10-Q, Quarterly Report
Jul-28-16 10:08AM  These 5 Stocks Under $10 Are Set to Soar Higher
Jul-23-16 02:01PM  Breakthrough Cancer Treatment Stocks Every Investor Ought to Know About at Motley Fool
Jul-19-16 02:44PM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : July 19, 2016 -7.09%
12:52PM  ETFs with exposure to NantKwest, Inc. : July 19, 2016
Jul-13-16 08:45AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : July 13, 2016 -8.97%
Jun-30-16 12:23PM  ETFs with exposure to NantKwest, Inc. : June 30, 2016
Jun-28-16 09:21AM  Better Buy: NantKwest, Inc. vs. Ionis Pharmaceuticals at Motley Fool
Jun-20-16 09:02AM  NANTKWEST, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-08-16 02:25PM  ETFs with exposure to NantKwest, Inc. : June 8, 2016
Jun-07-16 11:07AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016
Jun-04-16 07:39PM  After NantHealth IPO, Patrick Soon-Shiong Prepares for Two More
Jun-02-16 03:32PM  Soon-Shiong's Latest Offering Is Risky at Bloomberg
May-20-16 04:47PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NantKwest, Inc. of Class Action Lawsuit and Upcoming Deadline NK GlobeNewswire
11:49AM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of NantKwest, Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of May 23, 2016 - NK PR Newswire
May-19-16 04:03PM  EXPANDED CLASS PERIOD: Goldberg Law PC Files Securities Class Action Lawsuit Against NantKwest, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire -14.52%
01:28PM  The Law Offices of Howard G. Smith Announces an Expanded Class Period in the Securities Class Action Lawsuit Pending Against NantKwest, Inc. Business Wire
12:03PM  DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit Against NantKwest, Inc. And Reminds Investors With Losses To Contact The Firm Accesswire
NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GORLIN STEVEDirectorSep 13Sale5.9339,604234,729246,280Sep 13 08:20 PM
GORLIN STEVEDirectorSep 12Sale6.0335,811215,833285,884Sep 12 06:12 PM
GORLIN STEVEDirectorSep 11Sale6.0353,307321,468321,695Sep 12 06:12 PM
GORLIN STEVEDirectorSep 08Sale6.1214,72390,117375,002Sep 12 06:12 PM
GORLIN STEVEDirectorJun 20Sale7.7840,000311,200389,725Jun 21 04:02 PM
Thomas John CDirectorJun 20Sale7.4640,000298,500278,655Jun 21 04:03 PM
Tajak Richard J.Chief Financial OfficerMar 23Option Exercise0.005,000014,859Mar 27 01:12 PM
Tajak Richard J.Chief Financial OfficerDec 23Option Exercise0.005,000011,575Dec 28 07:04 PM
Thomas John CDirectorNov 25Sale7.506,16846,260309,621Nov 29 05:42 PM
Thomas John CDirectorNov 23Sale7.507,00052,500315,789Nov 23 04:26 PM
Thomas John CDirectorNov 22Sale7.5013,00097,500322,789Nov 23 04:26 PM